Clinical Trials Browser

Completed × tislelizumab × 1 year × Clear all

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05116085 2026-02-13

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Phase 2 Completed

33 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Phase 2 Completed

121 enrolled 25 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05254847 2026-01-20

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Phase 2 Completed

65 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT05532319 2025-12-30

FRONT-1

Phase 2 Completed

64 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

Phase 1 Completed

9 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05622071 2025-11-17

HESTIA

Phase 2 Completed

50 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03412773 2025-10-14

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Phase 3 Completed

684 enrolled 43 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03744468 2025-10-02

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Completed

114 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04047186 2025-09-23

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Phase 2 Completed

12 enrolled

Thoracic

Lung Neoplasms, Multiple Pulmonary Nodules

NCT05014815 2025-09-16

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

272 enrolled 17 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Phase 1/2 Completed

53 enrolled 17 charts

Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05014828 2025-08-24

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

Phase 2 Completed

58 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT05880082 2025-08-24

PPIO-004-EC001

Phase 2 Completed

118 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04047862 2025-08-22

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1 Completed

446 enrolled 49 charts

Other solid neoplasm

Locally Advanced and Metastatic Solid Tumors

NCT06333769 2025-08-15

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Phase 2 Completed

38 enrolled

Gastrointestinal

Mid-low Rectal Cancer

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

Completed

291 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

23 enrolled

Head & Neck

Head and Neck Neoplasms

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Phase 3 Completed

649 enrolled 22 charts

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

65 enrolled

Gastrointestinal

Stomach Neoplasms

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

108 enrolled

Gynecologic

Ovarian Neoplasms

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05542342 2025-05-14

SITISVEAL

Phase 2 Completed

16 enrolled

Dermatologic

Uveal Melanoma

NCT03957590 2025-05-02

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3 Completed

370 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04693234 2025-04-27

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

178 enrolled 26 charts

Gynecologic

Uterine Cervical Neoplasms

NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Phase 2 Completed

84 enrolled 17 charts

Other solid neoplasm

Advanced Solid Tumors

Clinical Trials

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

FRONT-1

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

HESTIA

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

PPIO-004-EC001

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

A Benefit Population Atlas of nICT Versus nCT for LAGC

neoCHANCE-1

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

TALENT

BRIGHT

neoCHANCE-2

SITISVEAL

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors